Lilly, Daiichi Explore Pharmacogenomic Marker For Prasugrel
This article was originally published in The Pink Sheet Daily
Executive Summary
Circulation study shows prasugrel metabolism unaffected by marker for Plavix non-response. Data won’t surprise FDA, but what will be the regulatory response?
You may also be interested in...
CER And Personalized Medicine Are "Synergistic" - FDA's Woodcock
The goals of comparative effectiveness research and personalized medicine might appear at odds or at least as leading to divergent paths, with one focusing on the best treatment for a population and the other on the best treatment for an individual
CER And Personalized Medicine Are "Synergistic" - FDA's Woodcock
The goals of comparative effectiveness research and personalized medicine might appear at odds or at least as leading to divergent paths, with one focusing on the best treatment for a population and the other on the best treatment for an individual
Plavix Pharmacogenomic Label Update May Help Lilly With Effient Launch
When Lilly's Effient (prasugrel) finally cleared FDA July 10, the first thing everyone noticed is the "black box" warning of a potential increased risk of bleeding associated with the antithrombotic drug